NewsMeter

OTLK's LYTENAVA wins FDA approval as first ophthalmic bevacizumab for wet AMD, targeting $8.5 billion retina market

7/25/2026

$8.5 billion is the estimated annual size of the U.S. anti-VEGF retina market that Outlook Therapeutics, Inc. (Nasdaq: OTLK) can now address commercially.

The FDA approved LYTENAVA (bevacizumab-vikg) on July 24, 2026, for neovascular age-related macular degeneration, making it the first FDA-approved ophthalmic formulation of bevacizumab in the United States.

Exclusivity and market position Outlook Therapeutics anticipates 12 years of Reference Product Exclusivity for LYTENAVA under the Biologics Price Competition and Innovation Act.

Bevacizumab already accounts for the majority of first-line anti-VEGF treatment in wet AMD, per Citeline (2023), Global Data (2023), and Market Scope (2022).